Mascot Study: Management of Atrial Fibrillation (AF) Suppression in AF-Heart Failure (HF) COmorbidity Therapy

Management of Atrial Fibrillation Suppression in AF-HF COmorbidity Therapy

The purpose of this study is to evaluate whether adding AF Suppression™ to cardiac resynchronization therapy (CRT) improves the prognosis of heart failure patients benefiting from cardiac resynchronization therapy.

Inclusion Criteria:

• HF patients
• New York Heart Association (NYHA) III - IV
• Spontaneous QRS ≥130 ms and/or mechanical interventricular delay > 50 ms
• Left ventricular ejection fraction (LVEF) ≤ 35%
• Left ventricular end diastolic diameter (LVEDD) ≥ 55 mm
• Optimized medical regimen
• Age > 18 years

Exclusion Criteria:

• Unstable angina or acute myocardial infarction (MI) (< 3 months)

• Coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA) < 3 months

• Life expectancy < 6 months

  • Permanent AF
  • Pregnancy